Similar Search Results

Are increasing 5-year survival rates evidence of success against cancer? : a reexamination using data from the US and Australia

Lichtenberg, Frank R. - In: Forum for health economics & policy : an evolving … 13 (2010) 2, pp. 1-16

Persistent link: https://www.econbiz.de/10009616652

The option value of innovation

Snider, Julia Thornton; Romley, John A.; Vogt, William B.; … - In: Forum for health economics & policy : an evolving … 15 (2012) 2, pp. 1-17

Persistent link: https://www.econbiz.de/10009620435

The impact of pharmaceutical innovation on cancer mortality in Belgium : 2004-2012

Lichtenberg, Frank R. - In: Forum for health economics & policy : an evolving … 20 (2017) 1, pp. 1-28

Persistent link: https://www.econbiz.de/10011701670

The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries : a two-way fixed-effects analysis

Lichtenberg, Frank R. - 2019

There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...

Persistent link: https://www.econbiz.de/10011987056

The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries : a two-way fixed-effects analysis

Lichtenberg, Frank R. - In: Forum for health economics & policy : an evolving … 21 (2018) 2, pp. 1-20

Persistent link: https://www.econbiz.de/10012022614

The option value of innovative treatments for metastatic melanoma

Snider, Julia Thornton; Seabury, Seth; Tebeka, Mahlet Gizaw - In: Forum for health economics & policy : an evolving … 21 (2018) 1, pp. 1-11

Persistent link: https://www.econbiz.de/10011896631